Characterization and improvement of anti-cancer properties of second generation antagonists of Mdm2 oncoprotein

2016/21/D/NZ7/00596

Keywords

Descriptors

  • NZ7_14: Farmacja, farmakoterapia, farmakologia
  • NZ1_1: Biologia molekularna
  • NZ3_3: Apoptoza

Panel

NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution

Uniwersytet Jagielloński, Wydział Chemii

Voivodeship: małopolskie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr Łukasz Skalniak

Number of co-investigators in the project: 4

Call

SONATA 11 – announced on 2016-03-15

Amount awarded
688 320 PLN
Project start date
2017-02-06
Project end date
2020-02-05
Project duration
36 months (the same as in the proposal)
Project status
Project settled

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Equipment purchased [PL]

  1. Komora laminarna II klasy bezpieczeństwa mikrobiologicznego. Cost: 17 958 PLN
  2. Komora laminarna II klasy bezpieczeństwa mikrobiologicznego.
  3. Zestaw zwiększający możliwości mikroskopu fluorescencyjnego. Cost: 95 000 PLN

Information in the final report

Publication in academic press/journals (8)

  1. A therapeutic patent overview of MDM2/X-Targeted Therapies (2014-2018)

    Authors:
    Skalniak L, Surmial E, Holak TA
    Academic press:
    Expert Opinion On Therapeutic Patents (year: 2019, volume: 46082, pages: 46042), Publisher: TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
    Status:
    Published
    DOI:
    10.1080/13543776.2019.1582645 – link to the publication
  2. Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists

    Authors:
    Kocik J, Machula M, Wisniewska A, Surmiak E, Holak TA, Skalniak L
    Academic press:
    Cancers (Basel) (year: 2019, volume: 11(7), pages: pii: E1014), Publisher: MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
    Status:
    Published
    DOI:
    10.3390/cancers11071014 – link to the publication
  3. Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

    Authors:
    Skalniak L, Kocik J, Polak J, Skalniak A, Rak M, Wolnicka-Glubisz A, Holak TA
    Academic press:
    Cancers (year: 2018, volume: 10, pages: 11), Publisher: MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
    Status:
    Published
    DOI:
    10.3390/cancers10110396 – link to the publication
  4. Fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells

    Authors:
    Skalniak L, Twarda-Clapa A, Neochoritis CG, Surmiak E, Machula M, Wisniewska A, Labuzek B, Ali AM, Krzanik S, Dubin G, Groves M, Dömling A, Holak TA
    Academic press:
    FEBS Journal (year: 2019, volume: 286(7), pages: 1360-1374), Publisher: WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
    Status:
    Published
    DOI:
    10.1111/febs.14774 – link to the publication
  5. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers

    Authors:
    Twarda-Clapa A, Krzanik S, Kubica K, Guzik K, Labuzek B, Neochoritis CG, Khoury K, Kowalska K, Czub M, Dubin G, Dömling A, Skalniak L, Holak TA
    Academic press:
    Journal of Medicinal Chemistry (year: 2017, volume: 60, pages: 4234-4244), Publisher: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
    Status:
    Published
    DOI:
    10.1021/acs.jmedchem.7b00104 – link to the publication
  6. Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction

    Authors:
    Neochoritis CG, Atmaj J, Twarda-Clapa A, Surmiak E, Skalniak L, Köhler LM, Muszak D, Kurpiewska K, Kalinowska-Tłuścik J, Beck B, Holak TA, Dömling A
    Academic press:
    European Journal of Medicinal Chemistry (year: 2019, volume: 182, pages: 111588), Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
    Status:
    Published
    DOI:
    10.1016/j.ejmech.2019.111588 – link to the publication
  7. Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions

    Authors:
    Ricardo MG, Ali AM, Plewka J, Surmiak E, Labuzek B, Neochoritis CG, Atmaj J, Skalniak L, Zhang R, Holak TA, Groves M, Rivera DG, Dömling A
    Academic press:
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (year: 2020, volume: 59(13), pages: 5235-5241), Publisher: WILEY-V C H VERLAG GMBH, POSTFACH 101161, 69451 WEINHEIM, GERMANY
    Status:
    Published
    DOI:
    10.1002/anie.201916257 – link to the publication
  8. Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint

    Authors:
    Magiera-Mularz K, Skalniak L, Zak KM, Musielak B, Rudzinska-Szostak E, Berlicki L, Kocik J, Grudnik P, Sala D, Zarganes‐Tzitzikas T, Shaabani S, Domling A, Dubin G, Holak TA
    Academic press:
    Angewandte Chemie International Edition (year: 2017, volume: 56, pages: 13732-13735), Publisher: WILEY-V C H VERLAG GMBH, POSTFACH 101161, 69451 WEINHEIM, GERMANY
    Status:
    Published
    DOI:
    10.1002/anie.201707707 – link to the publication

Articles in post-conference publications (1)

  1. Insufficient cancer cell elimination by p53-inducer Idasanutlin (R) (RG7388) leads to the generation of secondary drug-resistance

    Authors:
    Skalniak L, Kocik J, Rak M, Holak TA
    Conference:
    The 43'rd FEBS Congress (year: 2018, pages: 343-343), Publisher: WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
    Date:
    conference 7-12 lipca 2018
    Status:
    Published

« New search

Graphic design and implementation: Jakub Piotrowski